© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Glaukos Corporation (GKOS) stock surged +1.53%, trading at $152.96 on NYSE, up from the previous close of $150.65. The stock opened at $150.22, fluctuating between $149.45 and $154.36 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 08, 2026 | 151.39 | 154.61 | 149.45 | 152.96 | 1.06M |
| Jul 07, 2026 | 148.53 | 151.47 | 146.47 | 150.65 | 710.24K |
| Jul 06, 2026 | 150.00 | 150.26 | 146.69 | 148.70 | 712.92K |
| Jul 02, 2026 | 137.57 | 148.62 | 136.18 | 148.34 | 1.24M |
| Jul 01, 2026 | 139.06 | 141.40 | 136.23 | 137.57 | 707.68K |
| Jun 30, 2026 | 141.43 | 141.74 | 136.18 | 139.76 | 1.09M |
| Jun 29, 2026 | 143.51 | 143.70 | 139.86 | 142.19 | 1.24M |
| Jun 26, 2026 | 142.57 | 145.00 | 140.91 | 144.42 | 1.99M |
| Jun 25, 2026 | 139.60 | 145.39 | 137.52 | 142.57 | 787.69K |
| Jun 24, 2026 | 133.07 | 140.77 | 133.02 | 137.76 | 761.38K |
| Jun 23, 2026 | 131.69 | 135.23 | 131.25 | 134.65 | 546.3K |
| Jun 22, 2026 | 130.00 | 131.84 | 128.48 | 131.19 | 806.41K |
| Jun 18, 2026 | 128.97 | 131.73 | 125.43 | 130.68 | 984.18K |
| Jun 17, 2026 | 128.64 | 131.78 | 126.67 | 127.41 | 1.04M |
| Jun 16, 2026 | 130.68 | 132.24 | 127.09 | 127.53 | 724.43K |
| Jun 15, 2026 | 128.58 | 130.67 | 127.83 | 130.14 | 801.88K |
| Jun 12, 2026 | 124.97 | 128.27 | 122.69 | 126.81 | 707.97K |
| Jun 11, 2026 | 125.08 | 127.29 | 123.00 | 124.26 | 629.37K |
| Jun 10, 2026 | 122.00 | 125.96 | 119.66 | 122.49 | 1.54M |
| Jun 09, 2026 | 123.79 | 129.00 | 123.58 | 126.34 | 1.08M |
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
| Employees | 995 |
| Beta | 0.81 |
| Sales or Revenue | $314.71M |
| 5Y Sales Change% | 0.255% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |